omniture
Innovent Biologics,Inc

Latest News

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-26 08:00 4295

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 16, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-16 08:00 6117

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-12 08:12 2406

Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China

SAN FRANCISCO and SUZHOU, China, July 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-07-06 08:00 2329

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

SAN FRANCISCO and SUZHOU, China, June 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-06-29 08:00 2989

Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma

SAN FRANCISCO and SUZHOU, China, June 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-23 09:16 18431

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-21 08:00 2920

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-18 08:00 1453

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-15 12:00 2388

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 5570

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 5851

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 5801
12345 ... 7